RS for 70-year-old, 1.5-cm node-neg ER+ IDC? After 5 y continue/stop adj anastrozole?
Would you order an Oncotype DX assay for a 70-year-old postmenopausal woman with a 1.5-cm, node-negative, ER-positive, HER2-negative IDC?
Would you likely recommend that a 70-year-old postmenopausal woman with a 1.5-cm, node-negative IDC who received adjuvant TC and recently completed 5 years of anastrozole without problems continue or stop anastrozole therapy?
Biroschak JR et al. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation. Breast J 2013;19(3):269-75. Abstract
Goncalves R, Bose R. Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw 2013;11(2):174-82. Abstract
Long-term anastrozole versus tamoxifen treatment effects (LATTE). NCT01745289
Nagaraj G, Ma CX. Adjuvant chemotherapy decisions in clinical practice for early-stage node-negative, estrogen receptor-positive, HER2-negative breast cancer: Challenges and considerations. J Natl Compr Canc Netw 2013;11(3):246-50. Abstract
Zhu X et al. Systemic treatment decision making for patients with stage I and II, hormone receptor positive, her2/neu negative breast cancer. San Antonio Breast Cancer Symposium 2012;Abstract P3-04-11.